View Item 

Show simple item record

Alefacept therapy produces remission for patients with chronic plaque psoriasis
dc.contributor.authorKrueger, G. G.en_US
dc.contributor.authorEllis, C. N.en_US
dc.date.accessioned2010-06-01T22:08:57Z
dc.date.available2010-06-01T22:08:57Z
dc.date.issued2003-04en_US
dc.identifier.citationKrueger, G.G.; Ellis, C.N. (2003). "Alefacept therapy produces remission for patients with chronic plaque psoriasis." British Journal of Dermatology 148(4): 784-788. <http://hdl.handle.net/2027.42/75170>en_US
dc.identifier.issn0007-0963en_US
dc.identifier.issn1365-2133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75170
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12752139&dopt=citationen_US
dc.description.abstractBackground  Alefacept, human LFA-3/IgG 1 fusion protein, is a novel biological agent currently being developed for the treatment of chronic plaque psoriasis. Alefacept selectively reduces the memory-effector T cells that have been implicated in the pathogenesis of the disease; as a result, alefacept is classified as a therapy that induces remission (so-called ‘remittive’ therapy). In a previously published randomized, placebo-controlled phase II study of intravenous alefacept in 229 patients with chronic plaque psoriasis, clinical improvement was observed during dosing as well as in the postdosing follow-up period. Objectives  To assess the remission period following alefacept therapy. Methods  The time before re-treatment was required was measured in patients who were ‘clear’ or ‘almost clear’ of disease according to a physician global assessment at the end of the follow-up phase. Results  In these patients, responses were sustained for a median of 10 months, and for up to 18 months. No patient reported disease rebound after cessation of alefacept. Conclusions  Alefacept is a biological agent for the treatment of chronic plaque psoriasis that provides disease-free intervals and time off drug therapy.en_US
dc.format.extent175682 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rights2003 British Association of Dermatologistsen_US
dc.subject.otherAlefacepten_US
dc.subject.otherDisease Remissionen_US
dc.subject.otherDuration of Responseen_US
dc.subject.otherPsoriasisen_US
dc.titleAlefacept therapy produces remission for patients with chronic plaque psoriasisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Department of Dermatology, University of Michigan Medical School, 1910 Taubman Center 0314, Ann Arbor, MI 48109-0314, U.S.A.en_US
dc.contributor.affiliationotherDepartment of Dermatology, University of Utah Health Sciences Center, 50 North Medical Drive, Suite 4B 454, Salt Lake City, UT 84132, U.S.A.en_US
dc.identifier.pmid12752139en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75170/1/j.1365-2133.2003.05239.x.pdf
dc.identifier.doi10.1046/j.1365-2133.2003.05239.xen_US
dc.identifier.sourceBritish Journal of Dermatologyen_US
dc.identifier.citedreferenceEllis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277 – 84.en_US
dc.identifier.citedreferenceHiggins E, Munro C, Friedmann PS et al. Risk of relapse upon withdrawal of cyclosporin therapy for psoriasis. Lancet 1988; ii: 802 – 3.en_US
dc.identifier.citedreferenceGeorgala S, Koumantaki E, Rallis E et al. Generalized pustular psoriasis developing during withdrawal of long-term cyclosporin therapy. Br J Dermatol 2000; 142: 1057 – 8.en_US
dc.identifier.citedreferenceLim KK, Su WP, Schroeter AL et al. Cyclosporine in the treatment of dermatological disease: an update. Mayo Clin Proc 1996; 71: 1182 – 91.en_US
dc.identifier.citedreferenceMessana JM, Johnson KJ, Mihatsch MJ et al. Renal structure and function effects after low dose cyclosporine in psoriasis patients: a preliminary report. Clin Nephrol 1995; 43: 150 – 3.en_US
dc.identifier.citedreferenceThemido R, Loureiro M, Pecegueiro M et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol (Stockh) 1992; 72: 361 – 4.en_US
dc.identifier.citedreferenceSingri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138: 657 – 63.en_US
dc.identifier.citedreferenceKoo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51 – 9.en_US
dc.identifier.citedreferenceWalters IB, Burack LH, Coven TR et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999; 40: 893 – 900.en_US
dc.identifier.citedreferenceCoven TR, Murphy FP, Gilleaudeau P et al. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Arch Dermatol 1998; 134: 1263 – 8.en_US
dc.identifier.citedreferenceVallat VP, Gilleaudeau P, Battat L et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180: 283 – 96.en_US
dc.identifier.citedreferenceLindelof B, Sigurgeirsson B, Tegner E et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108 – 12.en_US
dc.identifier.citedreferenceShephard SE, Panizzon RG. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy. Dermatology 1999; 199: 106 – 12.en_US
dc.identifier.citedreferenceStern RS and the PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755 – 61.en_US
dc.identifier.citedreferenceMiller GT, Hochman PS, Meier W et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T-cell responses. J Exp Med 1993; 178: 211 – 22.en_US
dc.identifier.citedreferenceAustin LM, Ozawa M, Kikuchi T et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113: 752 – 9.en_US
dc.identifier.citedreferenceFriedrich M, Krammig S, Henze M et al. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/ effector type 1 immunophenotype. Arch Dermatol Res 2000; 292: 519 – 21.en_US
dc.identifier.citedreferenceSanders ME, Makgoba MW, Sharrow SO et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988; 140: 1401 – 7.en_US
dc.identifier.citedreferenceMajeau GR, Whitty A, Yim K et al. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2 + T cells is independent of cell activation. Cell Adhes Commun 1999; 7: 267 – 9.en_US
dc.identifier.citedreferenceChisholm PL, Williams CA, Jones WE et al. The effects of an immunomodulatory LFA3-IgG 1 fusion protein on nonhuman primates. Ther Immunol 1994; 1: 205 – 16.en_US
dc.identifier.citedreferenceMajeau GR, Meier W, Jimmo B et al. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T-cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753 – 67.en_US
dc.identifier.citedreferenceEllis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248 – 55.en_US
dc.identifier.citedreferenceMillard TP, Birch KE, Young ER. Treatment of plaque psoriasis. N Engl J Med 2001; 345: 1853 – 4 (Letter).en_US
dc.identifier.citedreferenceEllis CN, Krueger G, Shrager D. Repeated courses of alefacept therapy in chronic plaque psoriasis provide consistent efficacy and safety. J Eur Acad Dermatol Venereol 2001; 15: 246 (Abstr.).en_US
dc.identifier.citedreferenceCacoub P, Artru L, Canesi M et al. Life-threatening psoriasis relapse on withdrawal of cyclosporine. Lancet 1988; ii: 219 – 20.en_US
dc.identifier.citedreference26  Amevive® (alefacept) briefing document. Food and Drug Administration web site. Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3865B1 _01_Biogen.pdf. Accessed 27 May, 2002.en_US
dc.identifier.citedreferenceKrueger GG, Papp KA, Stough DB et al. for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821 – 33.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2133.2003.05239.x.pdf
Size:
171.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.